Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Long-Term Deferred Tax: 2017-2024

  • Dianthus Therapeutics' Long-Term Deferred Tax was N/A to $21.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $21.7 million, marking a year-over-year change of. This contributed to the annual value of $21.7 million for FY2024, which is N/A change from last year.
  • Dianthus Therapeutics' Long-Term Deferred Tax amounted to $21.7 million in Q4 2024, which was up 73.60% from $12.5 million recorded in Q4 2017.
  • In the past 5 years, Dianthus Therapeutics' Long-Term Deferred Tax ranged from a high of $21.7 million in Q4 2024 and a low of $21.7 million during Q4 2024.
  • Its 1-year average for Long-Term Deferred Tax is $21.7 million, with a median of $21.7 million in 2024.